ClinicalTrials.gg
Enrolling by invitationNCT07793409COLOSSUSUpdated Oct 21, 2026

A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 3 interventional study of Lunsekimig in Chronic Obstructive Pulmonary Disease, sponsored by Sanofi. Enrolling by invitation at 8 sites in 3 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Updated Oct 21, 2026Now Enrolling by invitationFirst site in Canada+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,508
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi — 7 open to participants now, 7 under way, 3 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sanofi.

Planned enrollment
Largest of 12
1,508 · median 937
Started
2026
with 2 others
Phase 3
8 of 15
3 open now
Registered
15th of 15
by date

Among the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, this one has the largest planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2026, is one of 8 in phase 3, and was the 15th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

7 of the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, or all of them as a file.
02

Study summary

This is an open-label, Phase 3, long-term safety extension study including participants of previous lunsekimig clinical trials with inadequately controlled chronic obstructive pulmonary disease (COPD ) characterized by an eosinophilic phenotype.

The purpose of the LTS 18211 study is to characterize the long-term safety and efficacy of lunsekimig in adults with COPD who completed studies EFC18243 or EFC18244 in the main study, and to assess the impact of inhaled corticosteroids (ICS ) withdrawal in the ICS withdrawal sub-study.

The study duration will be up to 100 weeks, including the following components:

  • Baseline Visit (Visit 1 / Week 0) will coincide with the End-of-Intervention visit from the parent study (EFC18243 or EFC18244) if possible
  • Treatment duration of up to 96 weeks
  • Safety follow-up period of approximately 4 weeks
  • The number of visits will be 26
03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who completed the treatment period of EFC18243 or EFC18244 studies, including EOI visit
  • for male and female participants during the study intervention period and during 8 weeks following the last administration of study intervention. And:

    • Female participants: not pregnant or breastfeeding, and one of the following conditions applies:

      • Is not a women of (WOCBP), OR
      • Is a WOCBP and agrees to follow the contraceptive guidance. The WOCBP should also agree not to donate or cryopreserve eggs (ova, oocytes) for the purpose of reproduction.
    • Male participants: No sperm donation or cryopreserving sperm

ICS-withdrawal sub-study only:

  • Participants receiving triple controller therapy (LABA+LAMA+ICS)
  • Participants who were compliant with lunsekimig
  • ≤ 1 moderate exacerbation and no severe exacerbation of during the parent study
  • No exacerbation during the run-in period

Exclusion criteria

Exclusion Criteria:

The exclusion criteria are identical for LTS18211 and ICS withdrawal sub-study:

  • Participant who developed a new medical condition or a change in status of an established medical condition or requires a new treatment or medication prior to enrollment that, per Investigator's medical judgement, would adversely affect participation of the participant in this study or would require permanent lunsekimig discontinuation, or participant potentially at risk of noncompliance to study procedures
  • Prescription drug or substance abuse, including alcohol, considered significant by the Investigator
  • History of or allergy to lunsekimig or to any of the used in the presentation or in preparation for administration of lunsekimig, or other allergy that, in the opinion of the Investigator, contraindicates participation in the study
  • Participants who are receiving prohibited concomitant medications at LTS18211 baseline
  • Participants who, during their participation in the parent study, developed an AE or an SAE deemed related to lunsekimig, and for whom continuation of treatment with lunsekimig may present an unreasonable risk

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,508 participants (estimated)

Study arms

  • Experimental
    Lunsekimig core study

    Subcutaneous (SC) administration of lunsekimig for up to 96 weeks, with the same inhaled controller medication as in the parent study (LABA + LAMA + ICS or LABA + LAMA)

    Drug: Lunsekimig

  • Experimental
    Lunsekimig sub-study with ICS maintenance

    ICS withdrawal sub-study: SC administration of lunsekimig for up to 96 weeks, with the inhaled controller medication LABA + LAMA + ICS in the run-in period followed by randomization to maintain the same inhaled regimen

    Drug: Lunsekimig

  • Experimental
    Lunsekimig sub-study with ICS withdrawal

    ICS withdrawal sub-study: SC administration of lunsekimig for up to 96 weeks, with the inhaled controller medication LABA + LAMA + ICS in the run-in period followed by randomization to withdraw ICS

    Drug: Lunsekimig

Interventions

  • * Pharmaceutical form: Solution for injection in prefilled syringe * Route of administration: Subcutaneous injection

    Also known as: SAR443765

06

What researchers measure

Primary outcomes

  1. Exposure-adjusted incidence rate of treatment-emergent adverse events (TEAE), including adverse events of special interest (AESI ) and serious adverse events (SAE)

    Exposure-adjusted incidence rate is defined as the number of patients with at least one specific treatment emergent adverse event in question per 100 patients taking the treatment for 1 year.

    Time frame: Study baseline to Week 100

  2. ICS withdrawal sub-study: Change from Week 12 (end of run-in period) to Week 36 in pre-Bronchodilator Forced Expiratory Volume in 1 second (pre-BD FEV1)

    Time frame: From Week 12 to Week 36

Secondary outcomes

  1. Annualized rate of moderate-to-severe COPD exacerbations

    Time frame: Study baseline to Week 96

  2. Change from parent study baseline in post-Bronchodilator Forced Expiratory Volume in 1 second (post-BD FEV1)

    Time frame: Parent study baseline to Weeks 48 and 96

  3. Change from parent study baseline in pre-BD FEV1

    Time frame: Parent study baseline to Weeks 48 and 96

  4. Change from parent study baseline in SGRQ-C total score

    The St. George's Respiratory Questionnaire (SGRQ) is a patient reported outcome measure designed to measure and quantify health status in adult patients with chronic airflow limitation. The SGRQ-C is a shorter (40 items) version derived from the original version using COPD data only. A global score ranges from 0 to 100 with lower scores indicating better quality-of-life.

    Time frame: Parent study baseline to Weeks 48 and 96

  5. ICS withdrawal sub-study: Time to first moderate or severe AECOPD

    AECOPD: acute exacerbation of chronic obstructive pulmonary disease

    Time frame: From Week 12 to Week 96

  6. ICS withdrawal sub-study: Change from Week 12 to Week 36 in SGRQ-C total score

    The St. George's Respiratory Questionnaire (SGRQ) is a patient reported outcome measure designed to measure and quantify health status in adult patients with chronic airflow limitation. The SGRQ-C is a shorter (40 items) version derived from the original version using COPD data only. A global score ranges from 0 to 100 with lower scores indicating better quality-of-life.

    Time frame: From Week 12 to Week 36

07

Study locations

8 sites
  • Newport Native MD- Site Number : 8403003
    Newport Beach, California 92663, United States
  • Helix Biomedics- Site Number : 8403065
    Boynton Beach, Florida 33435, United States
  • Deluxe Health Center- Site Number : 8403010
    Miami Lakes, Florida 33014, United States
  • Clinical Research Trials of Florida- Site Number : 8403011
    Tampa, Florida 33607, United States
  • Investigational Site Number : 1243004
    Guelph, Ontario N1h 6j2, Canada
  • Investigational Site Number : 1244050
    Saint-Charles-Borromée, Quebec J6E 2B4, Canada
  • Investigational Site Number : 8264013
    Chertsey, Surrey KT16 0PZ, United Kingdom
  • Investigational Site Number : 8264017
    Rotherham, S61 1AH, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jul 2031, 58 months after the start.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's planned 58 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2026
First posted
Aug 28, 2026
StartActual
Sep 16, 2026
Primary completionEst.
Jul 23, 2031
CompletionEst.
Jul 23, 2031
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Enrolling by invitation
changed Oct 21, 2026
Sites
5 sites added — first site in Canada
Show 5 added (2 United States, 2 Canada, 1 United Kingdom)
  • Deluxe Health Center- Site Number : 8403010 · Miami Lakes, United States
  • Clinical Research Trials of Florida- Site Number : 8403011 · Tampa, United States
  • Investigational Site Number : 1243004 · Guelph, Canada
  • Investigational Site Number : 1244050 · Saint-Charles-Borromée, Canada
  • Investigational Site Number : 8264013 · Chertsey, United Kingdom
Oct 21, 2026
Contact
No study contact listed any more: removed C•••@sanofi.com · •••1610
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Recruiting→Enrolling by invitation
    5 sites added — first site in Canada
    Show 5 added (2 United States, 2 Canada, 1 United Kingdom)
    • Deluxe Health Center- Site Number : 8403010 · Miami Lakes, United States
    • Clinical Research Trials of Florida- Site Number : 8403011 · Tampa, United States
    • Investigational Site Number : 1243004 · Guelph, Canada
    • Investigational Site Number : 1244050 · Saint-Charles-Borromée, Canada
    • Investigational Site Number : 8264013 · Chertsey, United Kingdom
    Contact No study contact listed any more: removed C•••@sanofi.com · •••1610
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07793409
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 28, 2026
Start date
Sep 16, 2026
Primary completion
Jul 23, 2031 (estimated)
Completion
Jul 23, 2031 (estimated)
Last update
Oct 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lunsekimig

Start the discussion